

SECTION-1: Identification of the substance / mixture and the company / undertaking

Catalogue Number	CS-O-32608
Product Name	Propamocarb hydrochloride
CAS No.	25606-41-1
Category	Pesticide Standards
Synonyms	propyl N-[3-(dimethylamino)propyl]carbamate;hydrochloride
Brand	Clearsynth Labs Ltd.
Identified uses	Laboratory Chemicals
Uses advised against	Not available
Company	Clearsynth Labs Ltd. Mumbai, India
Emergency Phone #	+91-22-245045900
REACH No.	Not available

SECTION 2: Hazards identification

Disclaimer: This is sample MSDS. Please email sales@clearsynth.com for more details.

2.1 Classification of the substance or mixture-Regulation (EC) No 1272/2008:

Skin irritation (Category 2)

2.2 Label Elements

Signal Word: Warning



Hazard Statement(s)

Code	Statement
H315	Causes skin irritation.
H317	May cause an allergic skin reaction.

Precautionary Statement(s)

Code	Statement
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P264	Wash hands thoroughly after handling.
P272	Not available
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P302+P352	IF ON SKIN: Wash with plenty of water and soap.
P321	Specific treatment (see ... on this label).
P332+P317	If skin irritation occurs: Get medical help.
P333+P317	Not available
P362+P364	Take off contaminated clothing and wash it before reuse.
P501	Dispose of contents/container in accordance with local/regional/national/international regulation

SECTION 3: Composition / information on ingredients

3.1 Substance

Component : Propamocarb hydrochloride

CAS Number : 25606-41-1

Molecular Formula : C₉H₂₁CIN₂O₂

Molecular Weight : 224.73

Parent Chemical : -

Synonyms : propyl N-[3-(dimethylamino)propyl]carbamate;hydrochloride

Concentration : Not available

SECTION 4: First aid measures

SECTION 4: First-aid measures

4.1 Description of first aid measures

General advice: Remove contaminated clothing and shoes. Seek medical attention if symptoms persist or are severe.

Inhalation: Move person to fresh air. Keep at rest. If breathing is difficult, seek medical attention.

Skin contact: Wash with plenty of soap and water. Get medical attention if irritation develops or persists.

Eye contact: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do.

Continue rinsing. Seek medical attention if irritation persists.

Ingestion: Rinse mouth. Do NOT induce vomiting unless directed by medical personnel. Never give anything by mouth to an unconscious person. Seek medical attention.

4.2 Most important symptoms and effects, both acute and delayed

Not available.

4.3 Indication of any immediate medical attention and special treatment needed

Treat symptomatically. No data available.

SECTION 5: Firefighting measures

SECTION 5: Fire-fighting measures

5.1 Extinguishing media

Suitable extinguishing media: Water spray, alcohol-resistant foam, dry chemical, carbon dioxide.

Unsuitable extinguishing media: Not available.

5.2 Special hazards arising from the substance or mixture

May decompose under fire conditions to release irritating and/or toxic fumes. Specific decomposition products: Not available.

5.3 Advice for firefighters

Wear self-contained breathing apparatus (SCBA) and full protective gear. Use water spray to cool unopened containers. Prevent fire-fighting water from entering drains or waterways.

SECTION 6: Accidental release measures

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Avoid breathing dust/vapors. Avoid contact with skin and eyes. Provide adequate ventilation. Wear appropriate personal protective equipment.

6.2 Environmental precautions

Avoid release to the environment. Prevent entry into drains, surface water, and soil.

6.3 Methods and material for containment and cleaning up

Contain spill. Collect spilled material using non-sparking tools and place in a suitable, labeled container for disposal. Avoid generating dust. Clean contaminated area with water and detergent as appropriate.

6.4 Reference to other sections

See Section 8 for personal protective equipment and Section 13 for disposal considerations.

SECTION-7: Handling and storage

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Handle in accordance with good industrial hygiene and safety practice. Avoid formation of dust and aerosols. Avoid contact with skin, eyes, and clothing. Do not eat, drink, or smoke when using this product. Wash hands thoroughly after handling.

7.2 Conditions for safe storage, including any incompatibilities

Store in a tightly closed container in a cool, dry, well-ventilated place. Protect from moisture. Keep away from incompatible materials.

Incompatible materials: Not available.

7.3 Specific end use(s)

Pesticide standard / laboratory use. Not for food, drug, or household use.

SECTION 8: Exposure controls / personal protection

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational exposure limits: Not available.

Biological limit values: Not available.

8.2 Exposure controls

Engineering controls: Use local exhaust ventilation or general ventilation to minimize exposure.

Personal protective equipment (PPE):

- Eye/face protection: Safety glasses with side shields or chemical splash goggles.
- Skin protection: Protective gloves (material not available). Wear protective clothing as appropriate.
- Respiratory protection: If ventilation is inadequate or dust/aerosols are generated, use an appropriate respirator (type not available).
- Hygiene measures: Wash hands after handling. Remove and wash contaminated clothing before reuse.

Environmental exposure controls: Avoid release to the environment; use appropriate containment.

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Test	Result
Appearance	No data available
IR spectrum	No data available
pH	No data available
Solubility	No data available

Property	Value
a) Physical State	No data available
b) Color	No data available
c) Odor	No data available
d) pH	No data available
e) Vapour Pressure	No data available
f) Viscosity	No data available
g) Initial Boiling Point and boiling range	No data available
h) Melting Point / Freezing Point	No data available

Property	Value
i) Auto Ignition Temperature	No data available
j) Flash Point	No data available
k) Explosion Limit, Lower	No data available
l) Explosion Limit, Upper	No data available
m) Decomposition Temperature	No data available
n) Loss on Drying	No data available
o) Relative Density	No data available
p) Solubility (in DMSO)	No data available
q) Oxidizing Properties	No data available

SECTION 10: Stability and reactivity

SECTION 10: Stability and reactivity

10.1 Reactivity

No data available.

10.2 Chemical stability

Stable under recommended storage conditions.

10.3 Possibility of hazardous reactions

No data available.

10.4 Conditions to avoid

Heat, open flames, and sources of ignition. Moisture (if applicable). Other conditions: Not available.

10.5 Incompatible materials

Not available.

10.6 Hazardous decomposition products

Not available.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

- Acute toxicity: Acute exposure to cholinesterase inhibitors can cause a cholinergic crisis characterized by severe nausea/vomiting, salivation, sweating, bradycardia, hypotension, collapse, and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. Accumulation of ACh at motor nerves causes overstimulation of nicotinic expression at the neuromuscular junction. When this occurs symptoms such as muscle weakness, fatigue, muscle cramps, fasciculation, and paralysis can be seen. When there is an accumulation of ACh at autonomic ganglia this causes overstimulation of nicotinic expression in the sympathetic system. Symptoms associated with this are hypertension, and hypoglycemia. Overstimulation of nicotinic acetylcholine receptors in the central nervous system, due to accumulation of ACh, results in anxiety, headache,

convulsions, ataxia, depression of respiration and circulation, tremor, general weakness, and potentially coma. When there is expression of muscarinic overstimulation due to excess acetylcholine at muscarinic acetylcholine receptors symptoms of visual disturbances, tightness in chest, wheezing due to bronchoconstriction, increased bronchial secretions, increased salivation, lacrimation, sweating, peristalsis, and urination can occur. Chronically high (>10 years) exposure leads to neuropsychological consequences including disturbances in perception and visuo-motor processing (A15321).

- Skin corrosion/irritation: No data available.
- Serious eye damage/eye irritation: No data available.
- Respiratory or skin sensitization: No data available.
- Germ cell mutagenicity: No data available.
- Carcinogenicity: No data available.
- Reproductive toxicity: No data available.
- STOT-single exposure: No data available.
- STOT-repeated exposure: Acute exposure to cholinesterase inhibitors can cause a cholinergic crisis characterized by severe nausea/vomiting, salivation, sweating, bradycardia, hypotension, collapse, and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. Accumulation of ACh at motor nerves causes overstimulation of nicotinic expression at the neuromuscular junction. When this occurs symptoms such as muscle weakness, fatigue, muscle cramps, fasciculation, and paralysis can be seen. When there is an accumulation of ACh at autonomic ganglia this causes overstimulation of nicotinic expression in the sympathetic system. Symptoms associated with this are hypertension, and hypoglycemia. Overstimulation of nicotinic acetylcholine receptors in the central nervous system, due to accumulation of ACh, results in anxiety, headache, convulsions, ataxia, depression of respiration and circulation, tremor, general weakness, and potentially coma. When there is expression of muscarinic overstimulation due to excess acetylcholine at muscarinic acetylcholine receptors symptoms of visual disturbances, tightness in chest, wheezing due to bronchoconstriction, increased bronchial secretions, increased salivation, lacrimation, sweating, peristalsis, and urination can occur. Chronically high (>10 years) exposure leads to neuropsychological consequences including disturbances in perception and visuo-motor processing (A15321).
- Aspiration hazard: No data available.

Likely routes of exposure

- No data available.

Symptoms related to the physical, chemical and toxicological characteristics

- Acute exposure to cholinesterase inhibitors can cause a cholinergic crisis characterized by severe nausea/vomiting, salivation, sweating, bradycardia, hypotension, collapse, and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. Accumulation of ACh at motor nerves causes overstimulation of nicotinic expression at the neuromuscular junction. When this occurs symptoms such as muscle weakness, fatigue, muscle cramps, fasciculation, and paralysis can be seen. When there is an accumulation of ACh at autonomic ganglia this causes overstimulation of nicotinic expression in the sympathetic system. Symptoms associated with this are hypertension, and hypoglycemia. Overstimulation of nicotinic acetylcholine receptors in the central nervous system, due to accumulation of ACh, results in anxiety, headache, convulsions, ataxia, depression of respiration and circulation, tremor, general weakness, and potentially coma. When there is expression of muscarinic overstimulation due to excess acetylcholine at muscarinic acetylcholine receptors symptoms of visual disturbances, tightness in chest, wheezing due to bronchoconstriction, increased bronchial secretions, increased salivation, lacrimation, sweating, peristalsis, and urination can occur. Chronically high (>10 years) exposure leads to neuropsychological consequences including disturbances in perception and visuo-motor processing (A15321).

SECTION 12: Ecological information

SECTION 12: Ecological information

12.1 Toxicity

Not available.

12.2 Persistence and degradability

Not available.

12.3 Bioaccumulative potential

Not available.

12.4 Mobility in soil

Not available.

12.5 Results of PBT and vPvB assessment

Not available.

12.6 Endocrine disrupting properties

Not available.

12.7 Other adverse effects

Not available.

SECTION 13: Disposal considerations

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Dispose of contents/container in accordance with local/regional/national/international regulations. Do not discharge to drains or the environment.

Product: Dispose of as hazardous waste if required by regulations; specific classification not available.

Contaminated packaging: Dispose of as unused product or according to local requirements after emptying/cleaning where permitted.

SECTION 14: Transport information

SECTION 14: Transport information

14.1 UN number

Not available.

14.2 UN proper shipping name

Not available.

14.3 Transport hazard class(es)

Not available.

14.4 Packing group

Not available.

14.5 Environmental hazards

Not available.

14.6 Special precautions for user

Not available.

14.7 Maritime transport in bulk according to IMO instruments

Not available.

SECTION 15: Regulatory information

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Not available.

15.2 Chemical safety assessment

Not available.

SECTION 16: Other information

SECTION 16: Other information

Product name: Propamocarb hydrochloride

Catalog No.: CS-O-32608

CAS No.: 25606-41-1

Synonyms: propyl N-[3-(dimethylamino)propyl]carbamate; hydrochloride

Supplier: Clearsynth Labs Ltd., Mumbai, India

Emergency phone: +91-22-245045900

Disclaimer: The information provided is believed to be accurate based on available data, but no warranty is expressed or implied. Users are responsible for determining suitability for their particular application and for compliance with applicable laws and regulations.

Revision date: Not available.

Version: Not available.

DISCLAIMER

This MSDS is system-generated. Please verify and confirm all data, statements, and values with the Support Team before use or distribution.